Enanta Pharmaceuticals Inc (NASDAQ: ENTA) kicked off on Tuesday, down -3.59% from the previous trading day, before settling in for the closing price of $12.82. Over the past 52 weeks, ENTA has traded in a range of $4.09-$15.34.
A company in the Healthcare sector has dropped its sales by -16.17% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 22.46%. With a float of $27.40 million, this company’s outstanding shares have now reached $28.85 million.
Enanta Pharmaceuticals Inc (ENTA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Enanta Pharmaceuticals Inc is 5.02%, while institutional ownership is 71.09%. The most recent insider transaction that took place on Feb 12 ’25, was worth 256,050. In this transaction President and CEO of this company bought 45,000 shares at a rate of $5.69, taking the stock ownership to the 846,638 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Chief Product Strategy Officer sold 2,283 for $8.06, making the entire transaction worth $18,401. This insider now owns 29,305 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.05 earnings per share (EPS), higher than consensus estimate (set at -1.35) by 0.3. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.10% during the next five years compared to -16.17% drop over the previous five years of trading.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Take a look at Enanta Pharmaceuticals Inc’s (ENTA) current performance indicators. Last quarter, stock had a quick ratio of 5.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.84, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -2.35 in one year’s time.
Technical Analysis of Enanta Pharmaceuticals Inc (ENTA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.33 million. That was inferior than the volume of 0.41 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.18%.
During the past 100 days, Enanta Pharmaceuticals Inc’s (ENTA) raw stochastic average was set at 66.54%, which indicates a significant increase from 64.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.81 in the past 14 days, which was higher than the 0.70 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.37, while its 200-day Moving Average is $7.68. However, in the short run, Enanta Pharmaceuticals Inc’s stock first resistance to watch stands at $13.34. Second resistance stands at $14.32. The third major resistance level sits at $15.09. If the price goes on to break the first support level at $11.59, it is likely to go to the next support level at $10.82. Assuming the price breaks the second support level, the third support level stands at $9.84.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Key Stats
The company with the Market Capitalisation of 356.62 million has total of 21,378K Shares Outstanding. Its annual sales at the moment are 67,640 K in contrast with the sum of -116,050 K annual income. Company’s last quarter sales were recorded 18,310 K and last quarter income was -18,260 K.
